DelveInsight’s “Thyroid Eye Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the Thyroid Eye Disease, historical and forecasted epidemiology as well as the Thyroid Eye Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Thyroid Eye Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Thyroid Eye Disease Market Forecast
Some of the key facts of the Thyroid Eye Disease Market Report:
The Thyroid Eye Disease market size was valued ~USD 1,993 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
In December 2024, Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company dedicated to developing best-in-class therapies for rare and serious conditions, has reported positive topline results from its Phase 3 THRIVE-2 clinical trial. The study evaluated veligrotug (veli), an intravenous (IV) anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with chronic thyroid eye disease (TED). TED is an autoimmune disorder marked by inflammation, tissue expansion, and damage in the areas surrounding and behind the eyes.
In 2022, the United States held the largest market share for Thyroid Eye Disease among the 7MM, with a valuation of around USD 1.98 billion. This figure is projected to grow further by 2034.
Among the pipeline therapies, three notable drugs—Viridian Therapeutics’ VRDN-001, Immunovant Sciences’ batoclimab, and Novartis’ COSENTYX (secukinumab)—are poised to make a substantial impact on expanding the Thyroid Eye Disease market.
In 2022, the United States reported approximately 1,012,000 prevalent cases of thyroid eye disease.
In 2022, the United States represented the largest share of thyroid eye disease cases, comprising approximately 42% of the total population across the 7MM. Germany contributed around 13%, while Japan accounted for about 8% of the total population share.
In 2022, Germany had the highest number of thyroid eye disease cases among the EU4 countries, followed by France, while Spain recorded the fewest cases.
DelveInsight estimates that in 2022, Japan had approximately 16,300 cases of acute Thyroid Eye Disease and 41,900 cases of chronic Thyroid Eye Disease. These numbers are expected to rise over the forecast period.
Key Thyroid Eye Disease Companies: Immunovant Sciences, Novartis, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, ACELYRIN Inc., Horizon Therapeutics USA, Inc., Neothetics, Inc, Sling Therapeutics, Inc., Novartis, and others
Key Thyroid Eye Disease Therapies: Batoclimab (IMVT 1401), COSENTYX (secukinumab), VRDN-001, Linsitinib, Aflibercept, VB421, RVT-140, lonigutamab, Teprotumumab, LIPO-102, Linsitinib, CFZ533, and others
The Thyroid Eye Disease epidemiology based on gender analyzed that the incidence of Thyroid Eye Disease is 16 per 100,000 females and 2.9 per 100,000 males with an approximate prevalence of 0.25% with no significant ethnic predisposition
The Thyroid Eye Disease market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Thyroid Eye Disease pipeline products will significantly revolutionize the Thyroid Eye Disease market dynamics.
Thyroid Eye Disease Overview
A complex orbital inflammatory condition that can be sight-threatening, incapacitating, and disfiguring is known as thyroid eye disease (TED). In honour of Robert J. Graves, an Irish doctor who first identified thyrotoxicosis in a woman presenting with goitre, rapid heartbeat, and exophthalmos, TED is also known as Graves’ ophthalmopathy.
Get a Free sample for the Thyroid Eye Disease Market Report
https://www.delveinsight.com/report-store/thyroid-eye-disease-market
Thyroid Eye Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Thyroid Eye Disease Epidemiology Segmentation:
The Thyroid Eye Disease market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:
Total Prevalence of Thyroid Eye Disease
Prevalent Cases of Thyroid Eye Disease by severity
Gender-specific Prevalence of Thyroid Eye Disease
Diagnosed Cases of Episodic and Chronic Thyroid Eye Disease
Download the report to understand which factors are driving Thyroid Eye Disease epidemiology trends @ Thyroid Eye Disease Epidemiology Forecast
Thyroid Eye Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Thyroid Eye Disease market or expected to get launched during the study period. The analysis covers Thyroid Eye Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Thyroid Eye Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Thyroid Eye Disease Therapies and Key Companies
Batoclimab (IMVT 1401): Immunovant Sciences
COSENTYX (secukinumab): Novartis
VRDN-001: Viridian Therapeutics
Linsitinib: Sling Therapeutics
Aflibercept: Regeneron Pharmaceuticals
VB421: ValenzaBio
Secukinumab: Novartis
RVT-1401: Immunovant Sciences GmbH
lonigutamab: ACELYRIN Inc.
Teprotumumab: Horizon Therapeutics USA, Inc.
LIPO-102: Neothetics, Inc
Linsitinib: Sling Therapeutics, Inc.
CFZ533: Novartis
Discover more about therapies set to grab major Thyroid Eye Disease market share @ Thyroid Eye Disease Treatment Market
Scope of the Thyroid Eye Disease Market Report
Study Period: 2020–2034
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
Thyroid Eye Disease Therapeutic Assessment: Thyroid Eye Disease current marketed and Thyroid Eye Disease emerging therapies
Thyroid Eye Disease Market Dynamics: Thyroid Eye Disease market drivers and Thyroid Eye Disease market barriers
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
Thyroid Eye Disease Unmet Needs, KOL’s views, Analyst’s views, Thyroid Eye Disease Market Access and Reimbursement
To know more about Thyroid Eye Disease companies working in the treatment market, visit @ Thyroid Eye Disease Clinical Trials and Therapeutic Assessment
Table of Contents
1. Thyroid Eye Disease Market Report Introduction
2. Executive Summary for Thyroid Eye Disease
3. SWOT analysis of Thyroid Eye Disease
4. Thyroid Eye Disease Patient Share (%) Overview at a Glance
5. Thyroid Eye Disease Market Overview at a Glance
6. Thyroid Eye Disease Disease Background and Overview
7. Thyroid Eye Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of Thyroid Eye Disease
9. Thyroid Eye Disease Current Treatment and Medical Practices
10. Thyroid Eye Disease Unmet Needs
11. Thyroid Eye Disease Emerging Therapies
12. Thyroid Eye Disease Market Outlook
13. Country-Wise Thyroid Eye Disease Market Analysis (2020–2034)
14. Thyroid Eye Disease Market Access and Reimbursement of Therapies
15. Thyroid Eye Disease Market Drivers
16. Thyroid Eye Disease Market Barriers
17. Thyroid Eye Disease Appendix
18. Thyroid Eye Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Gaurav BoraEmail: Send EmailPhone: +14699457679Address:304 S. Jones Blvd #2432 City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/
